Mark H. Stoler, MD - Figure 51

Results of a Phase III Efficacy Trial Comparing 9-Valent Human Papillomavirus (HPV) Vaccine (9vHPV) with quadrivalent HPV Vaccine (4vHPV), per protocol population* in females aged 16 through 26 years